pioneering next generation approaches to cure neurological conditions.
RECENT NEWS
Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson's Disease
Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the California Institute for Regenerative Medicine (CIRM) awarded an $8 million grant to Howard J. Federoff, M.D., Ph.D…
meet kenai therapeutics
We are a clinical-stage biotechnology company advancing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for the treatment of neurological conditions. Our aim is to deliver disease-modifying and potentially curative treatments that go beyond symptom management to reverse the impact of neurodegeneration – with the goal of restoring quality of life.